MedTrace Logo

Circulating Tumor Cells in Non-Small Cell Lung Carcinoma

NCT01830426 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 232

Last updated 2016-01-22

No results posted yet for this study

Summary

The purpose of this study is to establish the circulating tumor cell (CTC) assay as a surrogate for tissue diagnosis of suspected primary lung cancer. This is done through evaluating clinical and molecular markers to stratify the outcome/survival in patients with thoracic malignancies treated at Yale University/Yale-New Haven Hospital, University of California San Diego/Moores Cancer Center, Billings Clinic Cancer Center.

Conditions

  • Primary Lung Cancer

Sponsors & Collaborators

  • Yale University

    collaborator OTHER

  • Billings Clinic

    collaborator OTHER

  • University of California, San Diego

    collaborator OTHER

  • National Cancer Institute (NCI)

    collaborator NIH

  • Epic Sciences

    lead INDUSTRY

Principal Investigators

  • Ryan Dittamore, MBA · Epic Sciences

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2015-12-31
Completion
2016-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01830426 on ClinicalTrials.gov